Cargando…
Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
PURPOSE: The use process for chimeric antigen receptor T (CAR-T) cell drugs is complex and has been associated with a number of potentially severe complications, which requires management by a multidisciplinary team. Pharmacists are a key element in the team and have roles and responsibilities. Our...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992774/ https://www.ncbi.nlm.nih.gov/pubmed/33777790 http://dx.doi.org/10.3389/fonc.2021.636068 |
_version_ | 1783669448854470656 |
---|---|
author | Marzal-Alfaro, María Belen Escudero-Vilaplana, Vicente Revuelta-Herrero, Jose Luis Collado-Borrell, Roberto Herranz-Alonso, Ana Sanjurjo-Saez, Maria |
author_facet | Marzal-Alfaro, María Belen Escudero-Vilaplana, Vicente Revuelta-Herrero, Jose Luis Collado-Borrell, Roberto Herranz-Alonso, Ana Sanjurjo-Saez, Maria |
author_sort | Marzal-Alfaro, María Belen |
collection | PubMed |
description | PURPOSE: The use process for chimeric antigen receptor T (CAR-T) cell drugs is complex and has been associated with a number of potentially severe complications, which requires management by a multidisciplinary team. Pharmacists are a key element in the team and have roles and responsibilities. Our objective was to develop a structured and practical guide that supports hospital pharmacist responsibilities and defines specific activities in a CAR-T cell therapy program, specifically in Europe. METHODS: A literature review was performed, and the recommendations related to pharmacy practice in CAR-T therapy programs were analyzed. A multidisciplinary team was assembled, and meetings were held to address the key tasks in the CAR-T cells’ management process and to create the guide, based on national and international recommendations and in expert’s opinions. RESULTS: The multidisciplinary team defined the following key tasks and issued recommendations to improve patient safety, treatment efficacy, and quality: patient selection and evaluation, CAR-T cell drug order to manufacturer, apheresis and material shipment, reception of CAR-T cell drug and storing, CAR-T cell drug prescription and pharmacy verification, CAR-T cell drug thawing and dispensing, CAR-T cell drug administration, patient education, pharmacovigilance and monitoring and outcomes’ record and evaluation. In each task the pharmacist’s role and how it can improve patient care are defined. A checklist was created to guarantee the compliance of standard operating procedures approved in the institution to manage CAR-T cell therapy and as a tool to collect required data for outcomes’ record and evaluation. CONCLUSION: This article provides a consensus set of safety recommendations regarding CAR-T therapy management in clinical practice, easily implementable by other institutions in the European setting. The guide identifies key steps where the involvement of hospital pharmacists would improve the safety and quality of the process and is a support guide to standardize hospital pharmacists’ responsibilities within the multidisciplinary team. |
format | Online Article Text |
id | pubmed-7992774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79927742021-03-26 Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective Marzal-Alfaro, María Belen Escudero-Vilaplana, Vicente Revuelta-Herrero, Jose Luis Collado-Borrell, Roberto Herranz-Alonso, Ana Sanjurjo-Saez, Maria Front Oncol Oncology PURPOSE: The use process for chimeric antigen receptor T (CAR-T) cell drugs is complex and has been associated with a number of potentially severe complications, which requires management by a multidisciplinary team. Pharmacists are a key element in the team and have roles and responsibilities. Our objective was to develop a structured and practical guide that supports hospital pharmacist responsibilities and defines specific activities in a CAR-T cell therapy program, specifically in Europe. METHODS: A literature review was performed, and the recommendations related to pharmacy practice in CAR-T therapy programs were analyzed. A multidisciplinary team was assembled, and meetings were held to address the key tasks in the CAR-T cells’ management process and to create the guide, based on national and international recommendations and in expert’s opinions. RESULTS: The multidisciplinary team defined the following key tasks and issued recommendations to improve patient safety, treatment efficacy, and quality: patient selection and evaluation, CAR-T cell drug order to manufacturer, apheresis and material shipment, reception of CAR-T cell drug and storing, CAR-T cell drug prescription and pharmacy verification, CAR-T cell drug thawing and dispensing, CAR-T cell drug administration, patient education, pharmacovigilance and monitoring and outcomes’ record and evaluation. In each task the pharmacist’s role and how it can improve patient care are defined. A checklist was created to guarantee the compliance of standard operating procedures approved in the institution to manage CAR-T cell therapy and as a tool to collect required data for outcomes’ record and evaluation. CONCLUSION: This article provides a consensus set of safety recommendations regarding CAR-T therapy management in clinical practice, easily implementable by other institutions in the European setting. The guide identifies key steps where the involvement of hospital pharmacists would improve the safety and quality of the process and is a support guide to standardize hospital pharmacists’ responsibilities within the multidisciplinary team. Frontiers Media S.A. 2021-03-11 /pmc/articles/PMC7992774/ /pubmed/33777790 http://dx.doi.org/10.3389/fonc.2021.636068 Text en Copyright © 2021 Marzal-Alfaro, Escudero-Vilaplana, Revuelta-Herrero, Collado-Borrell, Herranz-Alonso and Sanjurjo-Saez http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Marzal-Alfaro, María Belen Escudero-Vilaplana, Vicente Revuelta-Herrero, Jose Luis Collado-Borrell, Roberto Herranz-Alonso, Ana Sanjurjo-Saez, Maria Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective |
title | Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective |
title_full | Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective |
title_fullStr | Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective |
title_full_unstemmed | Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective |
title_short | Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective |
title_sort | chimeric antigen receptor t cell therapy management and safety: a practical tool from a multidisciplinary team perspective |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992774/ https://www.ncbi.nlm.nih.gov/pubmed/33777790 http://dx.doi.org/10.3389/fonc.2021.636068 |
work_keys_str_mv | AT marzalalfaromariabelen chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective AT escuderovilaplanavicente chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective AT revueltaherrerojoseluis chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective AT colladoborrellroberto chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective AT herranzalonsoana chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective AT sanjurjosaezmaria chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective |